XML 330 R302.htm IDEA: XBRL DOCUMENT v3.25.1
Stockholders' Equity - Additional Information (Detail)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended
Mar. 31, 2022
USD ($)
Mar. 31, 2025
USD ($)
shares
Mar. 31, 2024
$ / shares
shares
Dec. 31, 2024
USD ($)
Vote
$ / shares
shares
Dec. 31, 2023
USD ($)
Vote
$ / shares
shares
Dec. 31, 2022
Vote
shares
Dec. 19, 2024
shares
Dec. 18, 2024
shares
Nov. 13, 2024
Jun. 07, 2024
shares
Jun. 06, 2024
shares
Mar. 01, 2022
USD ($)
Sale Of Stock [Line Items]                        
Common stock, shares authorized   58,251,629   58,251,629 58,251,629              
Common stock, shares issued   19,203,330   19,197,914 19,134,164              
Common stock, shares outstanding (in shares)   19,203,330   19,197,914 19,134,164              
Share Price | $ / shares     $ 0.62 $ 0.62 $ 0.52              
Underwriting discounts, commission and offering expenses | $   $ 1,606   $ 1,303                
Cara Therapeutics, Inc.                        
Sale Of Stock [Line Items]                        
Common stock, shares authorized   16,666,667   16,666,667 8,333,333   16,666,667 200,000,000   200,000,000 100,000,000  
Common stock, shares issued   1,524,535   1,523,743 1,513,353              
Common stock, shares outstanding (in shares)   1,524,535   1,523,743 1,513,353              
Preferred stock, shares issued   0   0 0              
Preferred stock, shares outstanding   0   0 0              
Quorum requirement reduction to vote                 0.33      
Number of votes for each share of common stock | Vote       1 1 1            
Net proceeds from sales of common stock under open market sales agreement | $         $ 1,117              
Unsold Securities Under Shelf Registration Statement dated April 4, 2019 [Member] | Cara Therapeutics, Inc.                        
Sale Of Stock [Line Items]                        
Aggregate offering price of securities | $                       $ 154,500
Open Market Sales Agreement [Member] | Jeffries LLC [Member] | Cara Therapeutics, Inc.                        
Sale Of Stock [Line Items]                        
Common stock, shares issued       0 10,747              
Stock Sale Commission Percentage 3.00%                      
Net proceeds from sales of common stock under open market sales agreement | $         $ 1,117,000              
Open Market Sales Agreement [Member] | Jeffries LLC [Member] | Maximum [Member] | Cara Therapeutics, Inc.                        
Sale Of Stock [Line Items]                        
Aggregate offering price of securities | $ $ 80,000                      
2022 Shelf Registration Statement [Member] | Maximum [Member] | Cara Therapeutics, Inc.                        
Sale Of Stock [Line Items]                        
Aggregate offering price of securities | $                       $ 300,000
Common Stock [Member]                        
Sale Of Stock [Line Items]                        
Common stock, shares issued   19,203,330 19,197,914 19,197,914 19,134,164 19,127,914            
Time-based Restricted Stock Units [Member] | Common Stock [Member] | Cara Therapeutics, Inc.                        
Sale Of Stock [Line Items]                        
Restricted stock units, vested   792 1,274 6,487 5,646 5,337            
Performance-Based Restricted Stock Units | Common Stock [Member] | Cara Therapeutics, Inc.                        
Sale Of Stock [Line Items]                        
Restricted stock units, vested   0 3,903 3,903 0 2,114